CCR2 and neoplasm: In line with the T cell-inflamed TME, we detected a transient infiltration of inflammatory CCR2+ monocytes, Mono(ACT), pDC and DN DC on tumor-targeted therapy that was abrogated in resistant tumors (figure 3C).